| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| ImmunoGen, Inc. | EVP R&D & MEDICAL AFFAIRS | Common Stock | 0 | $0 | $29.30 | Feb 12, 2024 | Direct |
| ImmunoGen, Inc. | EVP R&D & MEDICAL AFFAIRS | Restricted Stock Unit | 0 | $0 | $29.30 | Feb 12, 2024 | Direct |
| ImmunoGen, Inc. | EVP R&D & MEDICAL AFFAIRS | Stock Option (Right to Buy) | 0 | $0 | $5.19 | Feb 12, 2024 | Direct |
| Day One Biopharmaceuticals, Inc. | Head of Research and Dev. | Stock Option (right to buy Common Stock) | 346K | Jun 16, 2025 | Direct | ||
| Day One Biopharmaceuticals, Inc. | Head of Research and Dev. | Restricted Stock Unit (RSU) | 226K | Jun 16, 2025 | Direct | ||
| Magenta Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 40K | Aug 15, 2022 | Direct | ||
| Kura Oncology, Inc. | Director | Option to purchase common stock | 28.5K | Jun 5, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| DAWN | Day One Biopharmaceuticals, Inc. | Jun 16, 2025 | 2 | $0 | 4 | Jun 18, 2025 | Head of Research and Dev. |
| DAWN | Day One Biopharmaceuticals, Inc. | Jun 16, 2025 | 0 | $0 | 3 | Jun 18, 2025 | Head of Research and Dev. |
| KURA | Kura Oncology, Inc. | Jun 5, 2025 | 1 | $0 | 4 | Jun 6, 2025 | Director |
| KURA | Kura Oncology, Inc. | Sep 13, 2024 | 0 | $0 | 3 | Sep 17, 2024 | Director |
| KURA | Kura Oncology, Inc. | Sep 13, 2024 | 2 | $0 | 4 | Sep 17, 2024 | Director |
| IMGN | ImmunoGen, Inc. | Feb 12, 2024 | 3 | $0 | 4 | Feb 12, 2024 | EVP R&D & MEDICAL AFFAIRS |
| IMGN | ImmunoGen, Inc. | Feb 1, 2024 | 1 | $0 | 4 | Feb 5, 2024 | EVP R&D & MEDICAL AFFAIRS |
| IMGN | ImmunoGen, Inc. | Dec 29, 2023 | 1 | $21.2K | 4 | Jan 3, 2024 | EVP R&D & MEDICAL AFFAIRS |
| IMGN | ImmunoGen, Inc. | Dec 29, 2022 | 1 | $0 | 4 | Jan 3, 2023 | EVP R&D & MEDICAL AFFAIRS |
| IMGN | ImmunoGen, Inc. | Dec 29, 2022 | 0 | $0 | 3 | Jan 3, 2023 | EVP R&D & MEDICAL AFFAIRS |
| DNTH | Magenta Therapeutics, Inc. | Aug 15, 2022 | 1 | $0 | 4 | Aug 17, 2022 | Director |
| DNTH | Magenta Therapeutics, Inc. | Aug 15, 2022 | 0 | $0 | 3 | Aug 17, 2022 | Director |